Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts.
Teva Pharmaceutical Industries Ltd (TEVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ion Asset Management Stephen Levey And Jonathan Half | 39,033,500 | $599,944,895 | +7% | 38.81% |
| 2. | Rubric Capital Management David Rosen | 25,550,000 | $392,703,500 | +51% | 7.04% |
| 3. | Point State Capital Zach Schreiber | 15,131,488 | $232,570,971 | +12% | 3.37% |
| 4. | Glenview Capital Larry Robbins | 14,778,641 | $227,147,712 | +75% | 5.58% |
| 5. | Viking Global Andreas Halvorsen | 10,125,478 | $155,628,597 | +56% | 0.49% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.60 | 104,500 | $1,003,409.00 | 220,442 | 2019-06-04 | Filing | |
| $8.98 | 111,000 | $997,013.10 | 115,942 | 2019-06-03 | Filing | |
| $21.92 | 2,000 | $43,840.00 | 6,445 | 2018-08-03 | Filing | |
| $19.32 | 250,000 | $4,829,700.00 | 1,500,000 | 2018-05-10 | Filing | |
| $19.21 | 500,000 | $9,603,150.00 | 1,250,000 | 2018-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.08 | 55,775 | $952,464.10 | 403,288 | 2025-06-12 | Filing | |
| $17.02 | 6,206 | $105,627.98 | 9,989 | 2025-06-03 | Filing | |
| $18.04 | 337,915 | $6,097,304.47 | 150,996 | 2025-05-08 | Filing | |
| $15.90 | 48,385 | $769,369.89 | 48,384 | 2025-03-05 | Filing | |
| $15.91 | 22,576 | $359,272.21 | 96,769 | 2025-03-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,445,992 | $141,554,826 | 0.21% | |
| 2. | 226,534 | $3,796,710 | 0.04% | |
| 3. | 117,256 | $1,965,211 | 0.02% | |
| 4. | 110,653 | $1,854,544 | 0% | |
| 5. | 109,024 | $1,827,242 | 0.02% |
News See All
Teva's Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial
Teva Pharmaceutical (NYSE:TEVA) is one of the most undervalued large cap stocks to buy according to analysts.
16 Most Promising Stocks According to Wall Street Analysts
On July 3, Scott Wren, Wells Fargo senior global market strategist, and Adam Crisafulli, Vital Knowledge founder, joined 'Closing Bell Overtime' on CNBC to talk about the current market conditions.
13 Most Undervalued Large Cap Stocks to Buy According to Analysts
On July 3, Ben Preston, Portfolio Manager at Orbis Investments, appeared on CNBC to suggest that investors look past the constant political headlines and market volatility and find undervalued global ...
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bull’s thesis on TEVA.
Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
Billionaire Stan Druckenmiller's 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting significant advances in schizophrenia treatment.
Teva Pharmaceutical Industries Limited (TEVA) Study Finds Gaps in Tardive Dyskinesia Care at Long-Term Facilities
A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and treatment of tardive dyskinesia (TD) among residents in long-term care (LTC) facilities...
Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
Teva Pharma is an Israeli pharmaceutical company best known as one of the world’s largest manufacturers of generic drugs.
Billionaire Hedge Funds
